Abc Arbitrage 13F: New $5M Stake in Sanara MedTech (SMTI)

Abc Arbitrage opened a brand-new stake in Sanara MedTech Inc. SMTI, purchasing 140,894 shares valued at roughly $4.95 million, according to a Form 13F filed with the SEC on October 23, 2026. The filing covers institutional holdings for the period, showing the fund built a fresh position in the medical technology developer.

SMTI Sanara MedTech Inc.

$32.80 ▲ +41.99% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Abc Arbitrage's Sanara MedTech Inc. Position

The fund initiated a brand-new position in the healthcare company, acquiring 140,894 shares. The total reported value of the holding reached $4,951,015 based on the filing details. Prior to this report, the fund held no shares in Sanara MedTech Inc.

Other Institutional Activity in Sanara MedTech Inc.

Other large investors adjusted their holdings in Sanara MedTech Inc. during the period. Royal Bank of Canada reduced its holdings by 394 shares, ending with 130,995 shares worth about $4,296,635. AQR Capital Management, LLC grew its holdings by 72,269 shares, ending with 112,207 shares worth about $3,680,389. Renaissance Technologies, LLC grew its holdings by 2,723 shares, ending with 67,400 shares worth about $2,210,719. Squarepoint Ops LLC reduced its holdings by 19,792 shares, ending with 53,811 shares worth about $1,765,000. Jane Street Group, LLC grew its holdings by 12,223 shares, ending with 50,806 shares worth about $1,666,436.

Sanara MedTech Inc. Stock Up 0.1%

Sanara MedTech Inc. closed at $32.80 on October 23, 2026. The stock recently traded around $32.80 as of October 24, 2026, putting it about equal to its event-day close. The shares sit well above their 52-week low of $16.05 and below the 52-week high of $35.52.

Recent Earnings

Sanara MedTech Inc. reported trailing twelve-month revenue of $109,814,928 and a trailing twelve-month earnings per share of -$0.04. The firm has a forward P/E of 60.89. The company's next earnings report is scheduled for November 11, 2026.

Analysts Set New Price Targets

On July 30, 2026, HC Wainwright & Co. downgraded the stock with a Neutral rating and a $35.00 price target, down from its prior target of $36.00. The stock carries a consensus recommendation from three analysts with a target mean price of $35.00.

About Sanara MedTech Inc.

Sanara MedTech Inc. develops, markets, and distributes surgical solutions and wound care products for physicians, hospitals, and clinics in the United States. Its offerings include collagen-based products used for managing surgical and traumatic wounds as well as burns. Institutional interest from funds like Abc Arbitrage highlights how professional investors track the company's progress in the medical supply sector.

Bottom Line

Investors will watch for the company's upcoming earnings release on November 11, 2026, to gauge revenue growth and profitability updates. Future regulatory filings will show whether institutional interest in Sanara MedTech Inc. continues to expand.